Literature DB >> 30059656

Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice.

Terresa Kim1, Sol Kim1, Minju Song2, Cindy Lee1, Hideo Yagita3, Drake W Williams1, Eric C Sung4, Christine Hong5, Ki-Hyuk Shin6, Mo K Kang6, No-Hee Park7, Reuben H Kim8.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but detrimental intraoral lesion that predominantly occurs in patients with long-term use of antiresorptive agents, such as bisphosphonate and denosumab, a human anti-receptor activator of NF-κB ligand (RANKL) monoclonal antibody (Ab). Surgical intervention, such as tooth extraction, is a known risk factor for MRONJ, which is often performed to eliminate preexiting pathologic inflammatory conditions, such as periodontal diseases. Nonetheless, it remains unknown whether pre-existing periodontal disease condition exacerbates, or removal of such condition ameliorates, MRONJ development after tooth extraction. In this study, we combined the ligature-induced periodontitis and the tooth extraction mouse models under the administration of zoledronic acid (ZOL) or anti-RANKL Ab, and provide experimental evidence that a pre-existing pathologic inflammatory condition exacerbates MRONJ development after tooth extraction in mice. Under ZOL administration, tooth extraction alone induced ONJ lesions; however, extraction of a ligature-placed tooth further exacerbated ONJ development. When the ligature was removed and the inflammatory condition was deescalated, ONJ development was ameliorated. Anti-RANKL Ab administration resulted in similar outcomes. Interestingly, unlike ZOL-administered mice, anti-RANKL Ab-administered mice exhibited complete absence of osteoclasts, suggesting that physical presence of osteoclasts is not directly involved in ONJ development. Collectively, our study demonstrated that periodontal disease is a functionally linked risk factor that predisposes ONJ development after tooth extraction in the presence of bisphosphonate and denosumab.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30059656      PMCID: PMC6169128          DOI: 10.1016/j.ajpath.2018.06.019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  29 in total

Review 1.  Animal models to study host-bacteria interactions involved in periodontitis.

Authors:  Dana T Graves; Jun Kang; Oelisoa Andriankaja; Keisuke Wada; Carlos Rossa
Journal:  Front Oral Biol       Date:  2011-11-11

2.  Placement of free gingival grafts on denuded alveolar bone. Part II: microscopic observations.

Authors:  W C James; W T McFall; E J Burkes
Journal:  J Periodontol       Date:  1978-06       Impact factor: 6.993

3.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

4.  Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study.

Authors:  Ana Silva Martins; João André Correia; Francisco Salvado; Cecília Caldas; Nuno Santos; António Capelo; Paulo Palmela
Journal:  J Craniomaxillofac Surg       Date:  2017-07-28       Impact factor: 2.078

Review 5.  Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Authors:  S Ferrari-Lacraz; S Ferrari
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

6.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Authors:  Karim Fizazi; Allan Lipton; Xavier Mariette; Jean-Jacques Body; Yasmin Rahim; Julie R Gralow; Guozhi Gao; Ling Wu; Winnie Sohn; Susie Jun
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

7.  Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.

Authors:  Drake W Williams; Cindy Lee; Terresa Kim; Hideo Yagita; Hongkun Wu; Sil Park; Paul Yang; Honghu Liu; Songtao Shi; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  Am J Pathol       Date:  2014-08-28       Impact factor: 4.307

Review 8.  Matrix metalloproteinases and periodontal diseases.

Authors:  G Sapna; S Gokul; K Bagri-Manjrekar
Journal:  Oral Dis       Date:  2013-07-15       Impact factor: 3.511

9.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  21 in total

1.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

2.  Indigenous Microbiota Protects against Inflammation-Induced Osteonecrosis.

Authors:  D W Williams; H E Vuong; S Kim; A Lenon; K Ho; E Y Hsiao; E C Sung; R H Kim
Journal:  J Dent Res       Date:  2020-02-28       Impact factor: 6.116

3.  Porphyromonas gingivalis Impairs Oral Epithelial Barrier through Targeting GRHL2.

Authors:  W Chen; A Alshaikh; S Kim; J Kim; C Chun; S Mehrazarin; J Lee; R Lux; R H Kim; K H Shin; N H Park; K Walentin; K M Schmidt-Ott; M K Kang
Journal:  J Dent Res       Date:  2019-07-24       Impact factor: 6.116

4.  Long-Term Ligature-Induced Periodontitis Exacerbates Development of Bisphosphonate-Related Osteonecrosis of the Jaw in Mice.

Authors:  Drake Winslow Williams; Katie Ho; Allison Lenon; Sol Kim; Terresa Kim; Yousang Gwack; Reuben H Kim
Journal:  J Bone Miner Res       Date:  2022-06-09       Impact factor: 6.390

5.  Volumetric analysis of the periodontal microstructure under antiresorptive therapy: an experimental study in rabbits.

Authors:  Kathrin Becker; Robert Kerberger; Giulia Brunello; Joel Rockhoff; Nicole Rauch; Frank Schwarz
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

Review 6.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

7.  Local RANKL delivery improves socket healing in bisphosphonate treated rats.

Authors:  Akrivoula Soundia; Danny Hadaya; Yee Chau; Ioannis Gkouveris; Olga Bezouglaia; Sarah Dry; Flavia Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2021-04-07       Impact factor: 4.626

8.  Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization.

Authors:  Claudia Cristina Biguetti; André Hergesel De Oliva; Kent Healy; Ramez Hassan Mahmoud; Isabela Do Carmo Custódio; Dulce Helena Constantino; Edilson Ervolino; Marco Antonio Hungaro Duarte; Walid D Fakhouri; Mariza Akemi Matsumoto
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

9.  A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers.

Authors:  Satoe Okuma; Yuhei Matsuda; Yoshiki Nariai; Masaaki Karino; Ritsuro Suzuki; Takahiro Kanno
Journal:  Cancers (Basel)       Date:  2020-05-12       Impact factor: 6.639

10.  Rosuvastatin Prevents the Exacerbation of Atherosclerosis in Ligature-Induced Periodontal Disease Mouse Model.

Authors:  Jin Sook Suh; Sung Hee Lee; Zachary Fouladian; Jae Young Lee; Terresa Kim; Mo K Kang; Aldons J Lusis; Kristina I Boström; Reuben H Kim; No-Hee Park
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.